Monday, July 27, 1998
Janssen Pharmaceutica N.V.'s deal for Sepracor Inc.'s norcisapride,
a form of the active metabolite in Janssen's Propulsid, should not only extend
the life of the $1 billion heartburn drug, but the pharma company hopes that
fewer side effects and an added indication will elevate the drug's status from
a second line to a first line therapy.
Propulsid, indicated to treat nocturnal heartburn due to
gastroesophageal reflux disease (GERD), had